Eloralintide for knee osteoarthritis pain in adults who are overweight or have obesity
Tests eloralintide against placebo in adults with painful knee osteoarthritis and excess weight.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Key facts
- Where
- Ammon, Bellaire, Brooklyn, Buffalo, Burlington, Charlottesville, Chicago, Colorado Springs, Decatur, DeSoto, Evansville, Fort Worth, Fountain Valley, Houston, Jacksonville, Kirkland, Long Island City, Louisville, Mesa, Mobile, Newton, Phoenix, Plymouth Meeting, Quincy, Rochester, San Antonio, Santa Ana, Shavano Park, South Jordan, Spring Valley, St. Petersburg, Tucson, Tulsa, Walnut Creek, Weslaco, Winter Park, and Woodstock, United StatesSee the 39 sites
- Phase
- Phase 3
Where in United States
- Medical Research PartnersAmmon, United StatesTaking people
- JCCT - Juno Bellaire SiteBellaire, United StatesTaking people
- Ellipsis Research Group - Brooklyn - 7th StreetBrooklyn, United StatesTaking people
- Rochester Clinical Research - BuffaloBuffalo, United StatesTaking people
- Skylight Health Research - BurlingtonBurlington, United StatesTaking people
- Charlottesville Medical ResearchCharlottesville, United StatesTaking people
- Great Lakes Clinical Trials - RavenswoodChicago, United StatesTaking people
- Skylight Health Research - Colorado SpringsColorado Springs, United StatesTaking people
- Orita Clinical ResearchDecatur, United StatesTaking people
- Epic Medical Research - DeSotoDeSoto, United StatesTaking people
- Qualmedica Research, LLCEvansville, United StatesTaking people
- Valley Institute of Research - Fort WorthFort Worth, United StatesTaking people
- Ark Clinical Research, Fountain ValleyFountain Valley, United StatesTaking people
- Care Access - HoustonHouston, United StatesTaking people
- Westside Center for Clinical ResearchJacksonville, United StatesTaking people
- Paramount Clinical Research - Data Point Clinical ResearchKirkland, United StatesTaking people
- NYC Research Inc.Long Island City, United StatesTaking people
- Monroe Biomedical Research - LouisvilleLouisville, United StatesTaking people
- Care Access - 801 South Power Road, MesaMesa, United StatesTaking people
- Elite Pain and Spine Institute - South Crimson RoadMesa, United StatesTaking people
- AMR ClinicalMobile, United StatesTaking people
- AMR ClinicalNewton, United StatesTaking people
- Elite Clinical Studies, LLCPhoenix, United StatesTaking people
- Keystone Clinical StudiesPlymouth Meeting, United StatesTaking people
- Care Access - QuincyQuincy, United StatesTaking people
- Rochester Clinical Research, LLCRochester, United StatesTaking people
- Endeavor Clinical TrialsSan Antonio, United StatesTaking people
- VIP TrialsSan Antonio, United StatesTaking people
- Wolverine Clinical TrialsSanta Ana, United StatesTaking people
- Consano Clinical Research, LLCShavano Park, United StatesTaking people
- AMR ClinicalSouth Jordan, United StatesTaking people
- Encompass Clinical ResearchSpring Valley, United StatesTaking people
- Care Access - St. PetersburgSt. Petersburg, United StatesTaking people
- Tucson Orthopaedic Institute - North Wyatt DriveTucson, United StatesTaking people
- Central States ResearchTulsa, United StatesTaking people
- Diablo Clinical Research, Inc.Walnut Creek, United StatesTaking people
- Texas Valley Clinical ResearchWeslaco, United StatesTaking people
- Conquest ResearchWinter Park, United StatesTaking people
- North Georgia Clinical ResearchWoodstock, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07353931EU 2025-523768-19-00
- Record updated
- 4 November 2026
- Original description
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.Read full original descriptionShow less
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Inclusion: Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening; Have a stable body weight (less than 5% body weight change) for 90 days prior to screening; Have tried at least once to lose weight through diet but were unsuccessful; Have osteoarthritis of the knee and at least one of the following conditions:; Be over 50 years old; Have morning knee stiffness that lasts about 30 minutes; Have a crackling or grinding sound or feeling in the knee.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have an active knee infection; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.